HUP0105472A2 - Lineáris ciklodextrin kopolimerek és eljárás az előállításukra - Google Patents

Lineáris ciklodextrin kopolimerek és eljárás az előállításukra

Info

Publication number
HUP0105472A2
HUP0105472A2 HU0105472A HUP0105472A HUP0105472A2 HU P0105472 A2 HUP0105472 A2 HU P0105472A2 HU 0105472 A HU0105472 A HU 0105472A HU P0105472 A HUP0105472 A HU P0105472A HU P0105472 A2 HUP0105472 A2 HU P0105472A2
Authority
HU
Hungary
Prior art keywords
cyclodextrin
linear
cyclodextrin copolymers
copolymers
linear cyclodextrin
Prior art date
Application number
HU0105472A
Other languages
English (en)
Inventor
Mark E. Davis
Hector Gonzalez
Suzie Sue Jean Hwang
Original Assignee
California Institute Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Institute Of Technology filed Critical California Institute Of Technology
Publication of HUP0105472A2 publication Critical patent/HUP0105472A2/hu
Publication of HUP0105472A3 publication Critical patent/HUP0105472A3/hu
Publication of HU229473B1 publication Critical patent/HU229473B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Abstract

A találmány olyan lineáris ciklodextrin kopolimerekre vagy lineáris,oxidált ciklodextrin kopolimerekre, valamint azok előállításieljárására vonatkozik, amelyek (la) vagy (Ib) általános képletűismétlődő egységekből vagy azok keverékéből állnak, ahol C egyszubsztituált vagy szubsztituálatlan ciklodextrin monomer és A egy, aC ciklodextrinhez kapcsolódó segédmonomer. Ezek a vegyületek terápiásszerek bevitelére használhatók. Ó
HU0105472A 1998-07-01 1999-06-25 Linear cyclodextrin copolymers HU229473B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9155098P 1998-07-01 1998-07-01
US09/203,556 US6509323B1 (en) 1998-07-01 1998-12-02 Linear cyclodextrin copolymers
PCT/US1999/014298 WO2000001734A1 (en) 1998-07-01 1999-06-25 Linear cyclodextrin copolymers

Publications (3)

Publication Number Publication Date
HUP0105472A2 true HUP0105472A2 (hu) 2002-05-29
HUP0105472A3 HUP0105472A3 (en) 2003-03-28
HU229473B1 HU229473B1 (en) 2014-01-28

Family

ID=26784076

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0105472A HU229473B1 (en) 1998-07-01 1999-06-25 Linear cyclodextrin copolymers

Country Status (18)

Country Link
US (1) US6509323B1 (hu)
EP (2) EP1764112B1 (hu)
JP (2) JP4741729B2 (hu)
KR (1) KR100851315B1 (hu)
CN (1) CN100365024C (hu)
AT (1) ATE361321T1 (hu)
AU (1) AU763114C (hu)
BR (1) BR9911754B1 (hu)
CA (1) CA2336390C (hu)
CY (1) CY1106797T1 (hu)
DE (1) DE69935982T2 (hu)
DK (2) DK1764112T3 (hu)
ES (2) ES2403416T3 (hu)
HU (1) HU229473B1 (hu)
IL (2) IL140552A0 (hu)
MX (1) MXPA01000206A (hu)
PT (1) PT1093469E (hu)
WO (1) WO2000001734A1 (hu)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091192B1 (en) * 1998-07-01 2006-08-15 California Institute Of Technology Linear cyclodextrin copolymers
KR100848121B1 (ko) * 1998-07-01 2008-07-24 캘리포니아 인스티튜트 오브 테크놀로지 선형 사이클로덱스트린 공중합체
US6509323B1 (en) * 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
CA2353552A1 (en) * 1998-12-04 2000-06-15 California Institute Of Technology Supramolecular complexes containing therapeutic agents
US7375096B1 (en) * 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
US6740643B2 (en) * 1999-01-21 2004-05-25 Mirus Corporation Compositions and methods for drug delivery using amphiphile binding molecules
KR100371720B1 (ko) * 2000-07-03 2003-02-06 광주과학기술원 사이클로덱스트린 또는 이의 유도체와 이작용성 또는다작용성 히드록시 화합물의 축중합물, 및 이의 제조방법
TWI321054B (en) 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
EP1275404A1 (en) * 2001-07-11 2003-01-15 SCA Hygiene Products AB Odour regulation in hygiene products
EP1575976A4 (en) 2001-11-02 2006-08-23 Insert Therapeutics Inc METHODS AND COMPOSITIONS FOR THE THERAPEUTIC USE OF RNA INTERFERENCE
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
TW515107B (en) * 2001-12-25 2002-12-21 Solidlite Corp Power-saving light-emitting diode lamp
EP1476492A1 (en) * 2002-02-22 2004-11-17 Insert Therapeutics Inc. Carbohydrate-modified polymers, compositions and uses related thereto
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US7138105B2 (en) * 2002-02-27 2006-11-21 Pharmain Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
FR2842106B1 (fr) * 2002-07-11 2006-07-14 Centre Nat Rech Scient Dispersions aqueuses de particules nanometriques ou micrometriques pour l'encapsulation de composes chimiques
CN1694728B (zh) * 2002-09-06 2011-12-28 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
KR101476067B1 (ko) * 2002-09-06 2014-12-23 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
CA2501132A1 (en) * 2002-10-09 2004-04-22 Insert Therapeutics, Inc. Cyclodextrin-based materials, compositions and uses related thereto
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
PT1581236E (pt) * 2002-10-29 2013-12-24 Insmed Inc Libertação prolongada de anti-infecciosos
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
SG129240A1 (en) * 2003-01-23 2007-02-26 Agency Science Tech & Res Biodegradable copolymer and nucleic acid delivery system
CA2518475C (en) * 2003-03-07 2014-12-23 Alnylam Pharmaceuticals, Inc. Irna agents comprising asymmetrical modifications
US20070179100A1 (en) * 2003-04-09 2007-08-02 Muthiah Manoharan Protected monomers
EP1620544B1 (en) 2003-04-17 2018-09-19 Alnylam Pharmaceuticals Inc. MODIFIED iRNA AGENTS
CA2522349A1 (en) 2003-04-17 2004-11-04 Alnylam Pharmaceuticals, Inc. Protected monomers
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
US8796436B2 (en) 2003-04-17 2014-08-05 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US7851615B2 (en) * 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
US8017762B2 (en) * 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
EP1635763B1 (en) 2003-06-09 2012-08-08 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
US7927873B2 (en) 2003-12-19 2011-04-19 University Of Cincinnati Polyamides for nucleic acid delivery
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
EP1729724A4 (en) 2003-12-31 2008-07-23 Cydex Inc INHALATION FORMULATION WITH SULFOALKYL ETHER GAMMA CYCLODEXTRIN AND CORTICOSTEROID
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
EP2363483A3 (en) 2004-03-05 2014-07-16 Benitec, Inc. Multiple promoter expression cassettes for simultaneous delivery of RNAi agents
WO2005088655A1 (en) * 2004-03-12 2005-09-22 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A magnetoresistive medium
CA2569166C (en) * 2004-09-18 2011-02-15 Mirae Green Construction Co., Ltd. Apparatus for preventing soil inflow in intercepting sewer
JP2008526229A (ja) * 2005-01-06 2008-07-24 ベニテック，インコーポレーテッド 幹細胞の維持のためのＲＮＡｉ剤
WO2006084209A2 (en) * 2005-02-03 2006-08-10 Benitec, Inc. Rnai expression constructs
US8008468B2 (en) * 2005-02-16 2011-08-30 Benitec, Inc. RNAi expression constructs with liver-specific enhancer/promoter
DK1866414T3 (da) 2005-03-31 2012-04-23 Calando Pharmaceuticals Inc Inhibitorer af ribonukleotidreduktase-underenhed 2 og anvendelser deraf.
WO2006116756A1 (en) * 2005-04-28 2006-11-02 Benitec, Limited. Multiple-rnai expression cassettes for simultaneous delivery of rnai agents related to heterozygotic expression patterns
US8101741B2 (en) 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
EP3067046B1 (en) 2005-12-08 2020-03-25 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
WO2007072481A2 (en) * 2005-12-19 2007-06-28 Capsutech Ltd. Cyclodextrin-containing polymers and uses thereof
EP1971372B1 (en) 2005-12-19 2018-11-14 PharmaIN Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
JP2009526619A (ja) * 2006-02-15 2009-07-23 ティカ レーケメデル アーベー 質量減量を伴うコルチコステロイドの滅菌
US8501478B2 (en) 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
JP2010516625A (ja) * 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
JP2010539245A (ja) * 2007-09-14 2010-12-16 日東電工株式会社 薬物担体
WO2009041666A1 (ja) * 2007-09-28 2009-04-02 Nanodex Inc. 葉酸修飾されたシクロデキストリン化合物、その製造方法、標的指向性薬物送達システム用の薬物送達剤、医薬組成物及び造影剤
US8040246B2 (en) * 2007-12-04 2011-10-18 Avaya Inc. Systems and methods for facilitating a first response mission at an incident scene
US9006191B2 (en) 2007-12-27 2015-04-14 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering RNA
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
CN102037123A (zh) 2008-04-04 2011-04-27 卡兰多制药股份有限公司 Epas1抑制剂的组合物和用途
JP2011516094A (ja) 2008-04-15 2011-05-26 プロチバ バイオセラピューティクス インコーポレイティッド 干渉ｒｎａを用いたｃｓｎ５遺伝子発現のサイレンシング方法
EP2321414B1 (en) * 2008-07-25 2018-01-10 Alnylam Pharmaceuticals, Inc. Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand
US8309530B2 (en) * 2009-02-04 2012-11-13 Washington State University Compositions and methods for modulating ghrelin-mediated conditions
US9845237B2 (en) 2009-02-26 2017-12-19 The Regents Of The University Of California Supramolecular approach for preparation of size controllable nanoparticles
EP2503888A4 (en) 2009-11-23 2015-07-29 Cerulean Pharma Inc POLYMERS ON CYCLODEXTRINBASIS FOR THERAPEUTIC ADMINISTRATION
WO2011090940A1 (en) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
AU2011268146A1 (en) 2010-06-17 2013-01-10 Actogenix Nv Compositions and methods for treating inflammatory conditions
HUE037500T2 (hu) 2010-07-08 2018-08-28 Bonac Corp Egyszálú nukleinsav molekula a génexpresszió szabályozására
KR101894701B1 (ko) 2010-08-03 2018-09-04 가부시키가이샤 보낙 함질소 지환식 골격을 갖는 일본쇄 핵산 분자
WO2012017208A1 (en) 2010-08-04 2012-02-09 Cizzle Biotechnology Limited Methods and compounds for the diagnosis and treatment of
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
CA2816322A1 (en) 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compositions and methods for the treatment of cancer
WO2012145632A1 (en) * 2011-04-21 2012-10-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US20150240238A1 (en) 2011-11-17 2015-08-27 The Regents Of The University Of California Therapeutic rna switches compositions and methods of use
CA2859046C (en) 2011-12-14 2019-10-22 The Johns Hopkins University Nanoparticles with enhanced mucosal penetration or decreased inflammation
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
US9528111B2 (en) 2012-01-07 2016-12-27 Bonac Corporation Single-stranded nucleic acid molecule having amino acid backbone
RU2598627C2 (ru) 2012-01-19 2016-09-27 Дзе Джонс Хопкинс Юниверсити Композиции на основе наночастиц с улучшенным проникновением через слизистые оболочки
US20130196906A1 (en) * 2012-01-31 2013-08-01 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2013158710A2 (en) 2012-04-18 2013-10-24 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
SI2852391T1 (sl) 2012-05-21 2022-04-29 Insmed Incorporated Sistemi za obravnavo pljučnih infekcij
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
WO2015127389A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic enema formulations and methods of use
WO2015175545A1 (en) 2014-05-12 2015-11-19 The Johns Hopkins University Highly stable biodegradable gene vector platforms for overcoming biological barriers
US9937270B2 (en) 2014-05-12 2018-04-10 The John Hopkins University Engineering synthethic brain penetrating gene vectors
DK3466432T3 (da) 2014-05-15 2020-09-28 Insmed Inc Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
KR20170075742A (ko) 2014-10-02 2017-07-03 프로티바 바이오쎄라퓨틱스, 인코포레이티드 B형 간염 바이러스 유전자 발현을 제거하는 조성물 및 방법
AU2016211696B2 (en) 2015-01-27 2018-05-10 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CA2974123C (en) 2015-02-02 2023-08-01 Mei Pharma, Inc. Combination of benzopyran derivative and glycolytic inhibitors for cancer therapy
WO2016197132A1 (en) 2015-06-04 2016-12-08 Protiva Biotherapeutics Inc. Treating hepatitis b virus infection using crispr
CN108350455A (zh) 2015-07-29 2018-07-31 阿布特斯生物制药公司 用于使b型肝炎病毒基因表达沉默的组合物和方法
CN109153735A (zh) * 2016-01-21 2019-01-04 阿托恩波罗斯生命科学 基于环糊精的聚合物、其方法、组合物和应用
CN109476706A (zh) 2016-02-16 2019-03-15 耶鲁大学 用于促进靶向基因编辑的组合物及其使用方法
AU2017366721A1 (en) * 2016-12-01 2019-05-02 Ellipses Pharma Limited Treatment of cancer
WO2018159791A1 (ja) * 2017-03-02 2018-09-07 国立大学法人大阪大学 ホスト基含有重合性単量体、高分子材料及びその製造方法、並びに、包接化合物及びその製造方法
WO2018169960A1 (en) 2017-03-17 2018-09-20 The Johns Hopkins University Nanoparticle formulations for enhanced drug delivery to the bladder
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
EP3696269A4 (en) 2017-10-13 2021-09-01 Bonac Corporation SINGLE STRAND NUCLEIC ACID MOLECULE AND ITS PRODUCTION PROCESS
US10765638B2 (en) 2017-11-03 2020-09-08 Yale University Particle formulation with polycation complex
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
US20210189431A1 (en) 2018-08-10 2021-06-24 Yale University Compositions and methods for embryonic gene editing in vitro
CN110016194A (zh) * 2019-04-16 2019-07-16 无锡纯宇环保制品有限公司 一种有利于水体净化的可降解塑料袋
US20220243211A1 (en) 2019-06-21 2022-08-04 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
WO2020257779A1 (en) 2019-06-21 2020-12-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
WO2021022161A1 (en) 2019-07-31 2021-02-04 Yale University Compositions and methods for treating sickle cell disease
US20220370488A1 (en) 2019-10-22 2022-11-24 The Johns Hopkins University Mucus penetrating particle compositions and methods of use thereof enhancing immune response
US20230285576A1 (en) 2020-08-05 2023-09-14 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
US20230414700A1 (en) 2020-10-15 2023-12-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Tg2 inhibitors for improving mucociliary clearance in respiratory diseases
CN115160454A (zh) * 2021-04-01 2022-10-11 四川大学 一种基于聚-β-环糊精与金刚烷主客体作用的超分子多醛化合物及其制备方法
EP4352226A1 (en) 2021-06-07 2024-04-17 Yale University Peptide nucleic acids for spatiotemporal control of crispr-cas binding
WO2023064732A1 (en) 2021-10-15 2023-04-20 Georgia State University Research Foundation, Inc. Delivery of therapeutic recombinant uricase using nanoparticles
WO2023223787A1 (ja) * 2022-05-17 2023-11-23 リンテック株式会社 粘着性組成物、粘着剤、粘着シート、表示体および繰り返し屈曲デバイス

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32268E (en) * 1973-03-01 1986-10-21 Strategic Medical Research Corp. Therapeutic composition and method of therapeutically treating warm blooded animals therewith
JPS58167613A (ja) * 1982-03-26 1983-10-03 Mitsubishi Petrochem Co Ltd 水溶性シクロデキストリン含有重合体の製造法
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
EP0362290A4 (en) * 1987-06-17 1991-09-25 Princess Margaret Children's Medical Research Foundation (Inc.) Cloning of mite allergens
US4774329A (en) 1987-08-04 1988-09-27 American Maize-Products Company Controlled release agent for cetylpyridinium chloride
US4941996A (en) 1987-10-19 1990-07-17 Minnesota Mining And Manufacturing Company Inclusion complexes providing second harmonic generation
HU203899B (en) * 1988-05-03 1991-10-28 Forte Fotokemiai Ipar Process for producing gelatine-cyclodextreine polymeres
US4902788A (en) 1988-09-29 1990-02-20 Uop Crosslinked cyclodextrins supported on porous refractory inorganic oxides
JPH03221505A (ja) 1990-01-29 1991-09-30 Toppan Printing Co Ltd シクロデキストリンポリマーの合成方法及びシクロデキストリン膜の製造方法
IT1241417B (it) 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
DE4009825A1 (de) 1990-03-27 1991-10-02 Consortium Elektrochem Ind Wasserunloesliche cyclodextrin-polymerisate und verfahren zu deren herstellung
JPH0425505A (ja) * 1990-05-21 1992-01-29 Toppan Printing Co Ltd シクロデキストリンポリマー及びシクロデキストリン膜の製造方法
FR2665169A1 (fr) 1990-07-30 1992-01-31 Rhone Poulenc Chimie Composes d'inclusion de cyclodextrines enfermant des antioxydants phenoliques et leur utilisation dans les polymeres.
JPH04106101A (ja) * 1990-08-27 1992-04-08 Showa Denko Kk シクロデキストリンポリマーおよびその製造方法
JPH0586103A (ja) * 1990-10-01 1993-04-06 Toppan Printing Co Ltd シクロデキストリンポリマー
KR920702376A (ko) 1990-10-01 1992-09-03 후지다 히로미찌 시클로덱스트린 폴리머 및 그 폴리머를 이용한 시클로덱스트린막
WO1992009637A1 (fr) * 1990-11-30 1992-06-11 Toppan Printing Co., Ltd. Procede de production d'un derive de cyclodextrine et polymere contenant de la cyclodextrine immobilisee
CA2116431A1 (en) 1991-09-06 1993-03-18 Gurcharn S. Sidhu Composition and method for reducing cholesterol concentration
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
JP3221505B2 (ja) 1992-02-06 2001-10-22 日本信号株式会社 移動体の運行管理装置
IT1256134B (it) 1992-09-09 1995-11-29 Luigi Boltri Sali lipofili contenenti isotopi neutron attivabili e composizioni che li contengono
NZ258533A (en) 1992-11-30 1996-08-27 Ciba Geigy Ag Vinyl ester and amide derivatives of a dicarboxylic acid cyclic-oligomeric carbohydrate half ester; use for forming contact lenses, as thickeners, surfactants and lens cleaning agents
TW328535B (en) 1993-07-02 1998-03-21 Novartis Ag Functional photoinitiators and their manufacture
TW307775B (en) 1994-02-15 1997-06-11 Novartis Erfind Verwalt Gmbh Unsaturated carbohydrate derivatives, polymers thereof and their use
US5691316A (en) 1994-06-01 1997-11-25 Hybridon, Inc. Cyclodextrin cellular delivery system for oligonucleotides
US5776842A (en) 1994-06-23 1998-07-07 Cellresin Technologies, Llc Cellulosic web with a contaminant barrier or trap
JP3699141B2 (ja) 1994-09-24 2005-09-28 伸彦 由井 超分子構造の生体内分解性医薬高分子集合体及びその調製方法
JP3830198B2 (ja) 1996-03-29 2006-10-04 東光薬品工業株式会社 超分子構造高分子集合体を用いた皮膚透過性インドメタシン外用剤
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR100848121B1 (ko) * 1998-07-01 2008-07-24 캘리포니아 인스티튜트 오브 테크놀로지 선형 사이클로덱스트린 공중합체
US6509323B1 (en) * 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
CA2353552A1 (en) * 1998-12-04 2000-06-15 California Institute Of Technology Supramolecular complexes containing therapeutic agents
US6740643B2 (en) 1999-01-21 2004-05-25 Mirus Corporation Compositions and methods for drug delivery using amphiphile binding molecules
DK1102785T3 (da) 1999-06-07 2013-05-13 Arrowhead Res Corp Sammensætninger til lægemiddeltilførsel ved anvendelse af pH-følsomme molekyler
WO2000075162A1 (en) 1999-06-07 2000-12-14 Mirus Corporation A compound containing a labile disulfide bond
EP1233671A4 (en) 1999-11-29 2005-11-02 Mirus Corp COMPOSITIONS AND METHODS OF DISPOSING MEDICAMENTS USING AMPHIPHILIC BINDING MOLECULARS

Also Published As

Publication number Publication date
HU229473B1 (en) 2014-01-28
PT1093469E (pt) 2007-07-16
EP1093469A1 (en) 2001-04-25
ES2403416T3 (es) 2013-05-17
CN1308639A (zh) 2001-08-15
IL140552A0 (en) 2002-02-10
CA2336390C (en) 2011-02-22
MXPA01000206A (es) 2002-10-17
EP1764112A3 (en) 2007-05-23
EP1764112B1 (en) 2013-02-13
DK1093469T3 (da) 2007-09-17
BR9911754A (pt) 2001-11-06
JP2002519482A (ja) 2002-07-02
AU763114C (en) 2004-05-27
JP2011006695A (ja) 2011-01-13
JP4741729B2 (ja) 2011-08-10
CY1106797T1 (el) 2012-05-23
EP1093469B1 (en) 2007-05-02
CA2336390A1 (en) 2000-01-13
US6509323B1 (en) 2003-01-21
WO2000001734A1 (en) 2000-01-13
HUP0105472A3 (en) 2003-03-28
ATE361321T1 (de) 2007-05-15
CN100365024C (zh) 2008-01-30
DE69935982T2 (de) 2008-01-10
AU763114B2 (en) 2003-07-10
DE69935982D1 (en) 2007-06-14
IL140552A (en) 2006-10-31
DK1764112T3 (da) 2013-03-11
ES2285844T3 (es) 2007-11-16
EP1764112A2 (en) 2007-03-21
KR20010086293A (ko) 2001-09-10
BR9911754B1 (pt) 2010-07-13
AU4830599A (en) 2000-01-24
KR100851315B1 (ko) 2008-08-08

Similar Documents

Publication Publication Date Title
HUP0105472A2 (hu) Lineáris ciklodextrin kopolimerek és eljárás az előállításukra
GB0004128D0 (en) Novel compounds
HUP0202570A1 (hu) Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk
DK1200418T3 (da) Nematodicide trifluorbutener
HUP0203520A2 (hu) Bisz-acil-amidokat tartalmazó szilárd kozmetikai vagy gyógyszerészeti készítmény
ES2191208T3 (es) Oxiimino-pregnano-carbolactonas.
SE0102315D0 (sv) Compounds
DE69429524D1 (de) Aminocyclohexylester und ihre anwendung
CO4290432A1 (es) Nuevos derivados de pirazinacarboxamida, su preparacion y su utilizacion en medicamentos.
BG107220A (en) Antitumoral ecteinascudin derivatives
ATE200618T1 (de) Ssi tyrphostine und pharmazeutische zusammensetzungen
CY1109950T1 (el) Νεα παραγωγα 4,4-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικων) και συνθεσεις που τα περιεχουν
NO964238L (no) Halofantrin-fri-base for behandling av malaria og blandinger
HUP0202803A2 (en) Titanium derived compounds, preparation and use thereof
HUP0302515A2 (hu) Szulfamido-tienopirimidin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DK1204659T3 (da) Serotonerge benzofuraner
ATE263160T1 (de) Tocotrienolchinon- zyklisierungsprodukte mit antihypercholesterin wirkung
DE69812430T2 (de) Ketonperoxidderivate, ihre herstellung und verwendung
IL161116A (en) Use of irbesartan for the preparation of medicinal products that are useful for preventing or treating pulmonary arterial hypertension
NO970573L (no) Ylidenforbindelser og deres fremstilling
YU59403A (sh) Androgeni 7-supstituisani 11-halogenovani steroidi
TR199700963T1 (xx) Kardiyovask�ler hastal�klar�n tedavisi i�in aminotetralin t�revi.
DK0720617T3 (da) Hidtil ukendte urethanholdige aminosteroidforbindelser
UY27372A1 (es) Derivados de bencimidazol 1-aril-2-n, s u o-sustituidos, su uso para la obtención de medicamentos y preparados farmacéuticos que contienen estos derivados
FI980902A (fi) Levosimendaanin stabiileja koostumuksia